Value of repeat stimulated thyroglobulin testing in patients with differentiated thyroid carcinoma considered to be free of disease in the first year after ablation

Thyroid

Volumn 22, Issue 5, 2012, Pages 482-486

  Rosario, Pedro Weslley ^a,b   Furtado, Mariana Souza ^a   Mineiro Filho, Augusto Flávio Campos ^a   Lacerda, Rafela Xavier ^a   Calsolari, Maria Regina ^b  

^a Postgraduate Program   (Brazil)

^b Endocrinology Service   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROXINE;

ABLATION THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL EXAMINATION; DIFFERENTIATED THYROID CANCER; DISEASE FREE INTERVAL; ECHOGRAPHY; FEMALE; FOLLOW UP; HORMONAL REGULATION; HUMAN; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM METASTASIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENCE RISK; REPEAT PROCEDURE; SCHOOL CHILD; THYROGLOBULIN BLOOD LEVEL; THYROID FUNCTION TEST; THYROIDECTOMY; THYROXINE BLOOD LEVEL; WHOLE BODY SCINTISCANNING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; RECURRENCE; RISK; THYROGLOBULIN; THYROID GLAND; THYROID NEOPLASMS; THYROIDECTOMY; THYROXINE; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY;

EID: 84860469437     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2011.0214     Document Type: Article

References (24)

1. Pitoia F, Ward L, Wohllk N, Friguglietti C, Tomimori E, Gauna A, Camargo R, Vaisman M, Harach R, Munizaga F, Corigliano S, Pretell E, Niepomniszcze H 2009 Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. Arq Bras Endocrinol Metabol 53:884-887.
2. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W; European Thyroid Cancer Taskforce 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787-803.
3. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
4. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M 2000 Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 85:175-178.
5. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A 2002 Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 87:1499-1501.
6. Torlontano M, Attard M, Crocetti U, Tumino S, Bruno R, Costante G, D'Azzo G, Meringolo D, Ferretti E, Sacco R, Arturi F, Filetti S 2004 Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab 89:3402-3407.
7. Kloos RT, Mazzaferri EL 2005 A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 90:5047-5057.
8. Crocetti U, Durante C, Attard M, Maniglia A, Tumino S, Bruno R, Bonfitto N, Dicembrino F, Varraso A, Meringolo D, Filetti S, Trischitta V, Torlontano M 2008 Predictive value of recombinant human TSH stimulation and neck ultrasonography in differentiated thyroid cancer patients. Thyroid 18:1049-1053.
9. Castagna MG, Brilli L, Pilli T, Montanaro A, Cipri C, Fioravanti C, Sestini F, Capezzone M, Pacini F 2008 Limited value of repeat recombinant thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab 93:76-81.
10. Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, Wartofsky L 2011 Does an undetectable rhTSH-stimulated Tg level 12 months after initial treatment of thyroid cancer indicate remission? Clin Endocrinol (Oxf) 74:111-117.
11. Rosario PW, Borges MA, Valadão MM, Vasconcelos FP, Rezende LL, Padrão EL, Barroso AL, Purisch S 2007 Is adjuvant therapy useful in patients with papillary carcinoma smaller than 2cm? Thyroid 17:1225-1228.
12. Rosário PW, Fagundes TA, Purisch S 2004 Treatment of papillary microcarcinoma of the thyroid. Arq Bras Endocrinol Metabol 48:855-860.
13. Rosario PW, Faria S, Bicalho L, Gatti Alves MF, Borges MA, Purisch S, Padrao EL, Rezende LL, Barroso A 2005 Ultrasonographic differentiation between metastatic and benign lymph nodes in patients with papillary thyroid carcinoma. J Ultrasound Med 24:1385-1389.
14. Rosario PW, Tavares Jú nior WC, Biscolla RP, Purisch S, Maciel RM 2007 Usefulness of neck ultrasonography in the follow-up of patients with differentiated thyroid cancer. Arq Bras Endocrinol Metabol 51:593-600.
15. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A 2003 A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88:1433-1441.
16. do Rosário PW, Borges MA, Alves MF, Purisch S, Padrão EL, Rezende LL, Barroso AL 2006 Follow-up of high-risk patients with differentiated thyroid cancer without persistent disease after initial therapy. Arq Bras Endocrinol Metabol 50:909-913.
17. Leboulleux S, Rubino C, Baudin E, Caillou B, Hartl DM, Bidart JM, Travagli JP, Schlumberger M 2005 Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab 90:5723-5729.
18. Verburg FA, Stokkel MP, Düren C, Verkooijen RB, Mäder U, van Isselt JW, Marlowe RJ, Smit JW, Reiners C, Luster M 2010 No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 37:276-283.
19. Kim TY, Kim WB, Kim ES, Ryu JS, Yeo JS, Kim SC, Hong SJ, Shong YK 2005 Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 90:1440-1445.
20. Kloos RT 2010 Thyroid cancer recurrence in patients clinically free of disease with undetectable or very low serum thyroglobulin values. J Clin Endocrinol Metab 95:5241-5248.
21. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A 2010 Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20:1341-1349.
22. Valadão MM, Rosário PW, Borges MA, Costa GB, Rezende LL, Padrão EL, Barroso AL, Purisch S 2006 Positive predictive value of detectable stimulated Tg during the first year after therapy of thyroid cancer and the value of comparison with Tg-ablation and Tg measured after 24 months. Thyroid 16:1145-1149.
23. Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M 2003 Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 88:1107-1111.
24. Schlumberger M 2005 Is stimulation of thyroglobulin (Tg) useful in low-risk patients with thyroid carcinoma and undetectable Tg on thyroxin and negative neck ultrasound? Clin Endocrinol (Oxf) 62:119-120.